Bank of Italy Has $36.91 Million Stake in Qiagen (NYSE:QGEN)

Bank of Italy lifted its position in shares of Qiagen (NYSE:QGEN) by 30.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 847,881 shares of the company’s stock after acquiring an additional 196,756 shares during the quarter. Qiagen makes up about 1.2% of Bank of Italy’s investment portfolio, making the stock its 9th largest position. Bank of Italy’s holdings in Qiagen were worth $36,914,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in QGEN. Wellington Management Group LLP raised its position in shares of Qiagen by 81.0% during the third quarter. Wellington Management Group LLP now owns 6,054,116 shares of the company’s stock worth $245,299,000 after acquiring an additional 2,709,030 shares during the last quarter. Allspring Global Investments Holdings LLC grew its stake in shares of Qiagen by 33,220.7% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,345,488 shares of the company’s stock worth $58,435,000 after purchasing an additional 1,341,450 shares during the period. Massachusetts Financial Services Co. MA grew its stake in shares of Qiagen by 5.1% during the third quarter. Massachusetts Financial Services Co. MA now owns 22,257,083 shares of the company’s stock worth $901,412,000 after purchasing an additional 1,072,923 shares during the period. Jennison Associates LLC grew its stake in shares of Qiagen by 40.9% during the third quarter. Jennison Associates LLC now owns 1,131,808 shares of the company’s stock worth $45,838,000 after purchasing an additional 328,291 shares during the period. Finally, Assenagon Asset Management S.A. grew its stake in shares of Qiagen by 178.3% during the third quarter. Assenagon Asset Management S.A. now owns 503,592 shares of the company’s stock worth $20,405,000 after purchasing an additional 322,607 shares during the period. Institutional investors own 70.00% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently commented on QGEN shares. Morgan Stanley raised Qiagen from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $49.48 to $51.00 in a research note on Friday, February 16th. Citigroup decreased their price objective on Qiagen from $61.86 to $60.00 and set a “buy” rating for the company in a research note on Thursday, February 8th. Stifel Nicolaus decreased their price objective on Qiagen from $55.00 to $45.00 and set a “hold” rating for the company in a research note on Wednesday. Finally, JPMorgan Chase & Co. boosted their target price on Qiagen from $50.00 to $52.00 and gave the company an “overweight” rating in a research note on Thursday, February 8th. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $50.95.

Qiagen Trading Down 0.3 %

NYSE:QGEN traded down $0.12 on Thursday, reaching $42.69. The company’s stock had a trading volume of 1,202,042 shares, compared to its average volume of 1,228,031. The firm has a market cap of $9.74 billion, a PE ratio of 28.71, a PEG ratio of 3.58 and a beta of 0.42. The business’s 50-day moving average price is $42.56 and its two-hundred day moving average price is $42.71. Qiagen has a 1-year low of $34.74 and a 1-year high of $47.70. The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.62 and a current ratio of 1.99.

Qiagen (NYSE:QGEN) last issued its quarterly earnings results on Monday, April 29th. The company reported $0.46 EPS for the quarter, beating analysts’ consensus estimates of $0.44 by $0.02. The company had revenue of $459.00 million for the quarter, compared to analyst estimates of $453.91 million. Qiagen had a return on equity of 12.50% and a net margin of 17.38%. The company’s quarterly revenue was down 5.4% compared to the same quarter last year. During the same period in the previous year, the company posted $0.53 earnings per share. Equities research analysts anticipate that Qiagen will post 2.09 earnings per share for the current fiscal year.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.